210 related articles for article (PubMed ID: 19247654)
21. Dual time point 2-[18F]fluoro-2'-deoxyglucose positron emission tomography in chronic bacterial osteomyelitis.
Sahlmann CO; Siefker U; Lehmann K; Meller J
Nucl Med Commun; 2004 Aug; 25(8):819-23. PubMed ID: 15266177
[TBL] [Abstract][Full Text] [Related]
22. Dual-time-point [18F]-FDG PET/CT in the diagnostic evaluation of suspicious breast lesions.
Caprio MG; Cangiano A; Imbriaco M; Soscia F; Di Martino G; Farina A; Avitabile G; Pace L; Forestieri P; Salvatore M
Radiol Med; 2010 Mar; 115(2):215-24. PubMed ID: 20017002
[TBL] [Abstract][Full Text] [Related]
23. [
Justet A; Laurent-Bellue A; Thabut G; Dieudonné A; Debray MP; Borie R; Aubier M; Lebtahi R; Crestani B
Respir Res; 2017 Apr; 18(1):74. PubMed ID: 28449678
[TBL] [Abstract][Full Text] [Related]
24. [Quantitative comparison of idiopathic interstitial pneumonias on high-resolution computed tomographic findings].
Guo XJ; Bao N; Zhang L; Dai HP; Chen Q; Zhai RY; Zhai XL; Liu M; Wang C
Zhonghua Yi Xue Za Zhi; 2011 Jan; 91(1):11-5. PubMed ID: 21418954
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of dual-time-point 18F-FDG PET-CT imaging in patients with head and neck squamous cell carcinoma.
Abgral R; Le Roux PY; Rousset J; Querellou S; Valette G; Nowak E; Turzo A; Tissot V; Marianowski R; Salaün PY
Nucl Med Commun; 2013 Jun; 34(6):551-6. PubMed ID: 23587836
[TBL] [Abstract][Full Text] [Related]
26. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
[TBL] [Abstract][Full Text] [Related]
27. Dual-time-point FDG PET/CT for the evaluation of pediatric tumors.
Costantini DL; Vali R; Chan J; McQuattie S; Charron M
AJR Am J Roentgenol; 2013 Feb; 200(2):408-13. PubMed ID: 23345365
[TBL] [Abstract][Full Text] [Related]
28. The clinical value of texture analysis of dual-time-point
Nakajo M; Jinguji M; Aoki M; Tani A; Sato M; Yoshiura T
Eur Radiol; 2020 Mar; 30(3):1759-1769. PubMed ID: 31728684
[TBL] [Abstract][Full Text] [Related]
29. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
[TBL] [Abstract][Full Text] [Related]
30. Prospective evaluation of solitary thyroid nodule on 18F-FDG PET/CT and high-resolution ultrasonography.
D'Souza MM; Marwaha RK; Sharma R; Jaimini A; Thomas S; Singh D; Jain M; Bhalla PJ; Tripathi M; Tiwari A; Mishra A; Mondal A; Tripathi RP
Ann Nucl Med; 2010 Jun; 24(5):345-55. PubMed ID: 20373060
[TBL] [Abstract][Full Text] [Related]
31. Respiratory-gated imaging in metabolic evaluation of small solitary pulmonary nodules: 18F-FDG PET/CT and correlation with histology.
Farid K; Poullias X; Alifano M; Regnard JF; Servois V; Caillat-Vigneron N; Petras S
Nucl Med Commun; 2015 Jul; 36(7):722-7. PubMed ID: 25793929
[TBL] [Abstract][Full Text] [Related]
32. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
[TBL] [Abstract][Full Text] [Related]
33. Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease.
Mavi A; Basu S; Cermik TF; Urhan M; Bathaii M; Thiruvenkatasamy D; Houseni M; Dadparvar S; Alavi A
Mol Imaging Biol; 2009; 11(5):369-78. PubMed ID: 19472014
[TBL] [Abstract][Full Text] [Related]
34. The use of dual-phase 18F-FDG PET in characterizing thyroid incidentalomas.
Hsiao YC; Wu PS; Chiu NT; Yao WJ; Lee BF; Peng SL
Clin Radiol; 2011 Dec; 66(12):1197-202. PubMed ID: 21907336
[TBL] [Abstract][Full Text] [Related]
35. Characterization of solitary pulmonary nodules with 18F-FDG PET/CT relative activity distribution analysis.
Zhao L; Tong L; Lin J; Tang K; Zheng S; Li W; Cheng D; Yin W; Zheng X
Eur Radiol; 2015 Jul; 25(7):1837-44. PubMed ID: 25636419
[TBL] [Abstract][Full Text] [Related]
36. Idiopathic pulmonary fibrosis and diffuse parenchymal lung disease: implications from initial experience with 18F-FDG PET/CT.
Groves AM; Win T; Screaton NJ; Berovic M; Endozo R; Booth H; Kayani I; Menezes LJ; Dickson JC; Ell PJ
J Nucl Med; 2009 Apr; 50(4):538-45. PubMed ID: 19289428
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Zytoon AA; Murakami K; El-Kholy MR; El-Shorbagy E; Ebied O
Eur J Radiol; 2009 Jun; 70(3):530-8. PubMed ID: 18395387
[TBL] [Abstract][Full Text] [Related]
38. The role of FDG PET-CT in differential diagnosis of pleural pathologies.
Elboga U; Yılmaz M; Uyar M; Zeki Çelen Y; Bakır K; Dikensoy O
Rev Esp Med Nucl Imagen Mol; 2012; 31(4):187-91. PubMed ID: 23067687
[TBL] [Abstract][Full Text] [Related]
39. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
[TBL] [Abstract][Full Text] [Related]
40. Dual time point 2-deoxy-2-[18F]fluoro-D-glucose PET/CT: nodal staging in locally advanced breast cancer.
García Vicente AM; Soriano Castrejón A; Cruz Mora MÁ; Ortega Ruiperez C; Espinosa Aunión R; León Martín A; González Ageitos A; Van Gómez López O
Rev Esp Med Nucl Imagen Mol; 2014; 33(1):1-5. PubMed ID: 23707190
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]